|
|
|
|
|
|
|
|
|
|
|
30.06.26 - 17:01
|
/C O R R E C T I O N -- Ratio Therapeutics Inc./ (PR Newswire)
|
|
|
In the news release, Ratio Therapeutics Enters Strategic Actinium-225 Supply Agreement with PanTera to Support Radiopharmaceutical Development Programs, issued 30-Jun-2026 by Ratio Therapeutics Inc. over PR Newswire, we are advised by the company that changes have been made. The complete,......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22.04.26 - 13:01
|
Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting (PR Newswire)
|
|
|
ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potential In prostate cancer, ATNM-400 demonstrates efficacy across both high PSMA-expressing and, importantly, low PSMA-expressing prostate cancer models,......
|
|
|
|
|
|
|
|
|
30.03.26 - 22:03
|
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results (GlobeNewswire EN)
|
|
|
BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) applications for the Company to proceed to a Phase 1b clinical trial with AKY-25191. AKY-2519 is a miniprotein radioconjugate targeting B7-H3, which is expressed in several solid tumor types including prostate and lung cancers, and is the second clinical stage miniprotein radioconjugate discovered using Aktis' proprietary platform. The Company's lead miniprotein radioconjugate, AKY-1189, targeting Nectin-4, is currently enrolling patients in a Phase 1b clinical study. Aktis' miniprotein radioconjugates are designed to selectively deliver actinium-225 (225Ac), a highly potent alpha-emitting radioisotope, ...
|
|
|
19.03.26 - 13:36
|
Convergent Therapeutics Appoints Radiopharmaceutical Industry Veteran Michael Rossi to its Board of Directors (Business Wire)
|
|
|
Rossi Brings Decades of Leadership as Convergent Advances its Alpha-based Radioantibody for Prostate Cancer to Late-Stage Clinical DevelopmentCAMBRIDGE, Mass.--(BUSINESS WIRE)--Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation alpha-emitting radioantibodies for the treatment of prostate cancer, today announced the appointment of Michael Rossi to its Board of Directors. Mr. Rossi brings more than 30 years of experience in radiopharmaceuticals, drug development, and commercial leadership to Convergent, as the Company completes its Phase 2 study of CONV01-α, a prostate specific membrane antigen (PSMA)-targeted Actinium-225 (Ac-225) radioantibody in patients with metastatic castration-resistant prostate cancer (mCRPC).
Mr. Rossi currently serves as CEO of SHINE SPECT USA, LLC, a leader in diagnostic radiopharmaceuticals. He previously served as President, CEO, and a board member of Y-mAbs Therapeutics, where he was appointed CEO in 2023 and led until its acquisit...
|
|
|
17.03.26 - 14:09
|
TerraPower Isotopes announces cGMP manufacturing facility (PR Newswire)
|
|
|
This new facility will expand TPI's actinium-225 production twentyfold. BELLEVUE, Wash., March 17, 2026 /PRNewswire/ -- TerraPower Isotopes® (TPI®) announced today that the company is building its flagship current Good Manufacturing Practices (cGMP) actinium-225 (ac-225) manufacturing......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
